PDF(Pubmed)
Abstract：
Chronic kidney disease (CKD) is a global health concern and public health priority. The condition often involves inflammation due to the accumulation of toxins and the reduced clearance of inflammatory cytokines, leading to gradual loss of kidney function. Because of the tremendous burden of CKD, finding effective treatment strategies against inflammation is crucial. Substantial evidence suggests an association between kidney disease and the inflammasome. As a well-known multiprotein signaling complex, the NLR family pyrin domain containing 3 (NLRP3) inflammasome plays an important role in inducing renal inflammation and fibrosis. Small molecule inhibitors targeting the NLRP3 inflammasome are potential agents for the treatment of CKD.The NLRP3 inflammasome activation amplifies the inflammation response, promoting pyroptotic cell death. Thus, it may contribute to the onset and progression of CKD, but the mechanism behind inflammasome activation in CKD remains obscure.In this review, we summarized recent findings on the role of the NLRP3 inflammasome in CKD and new strategies targeting the NLRP3 inflammasome.
摘要：
慢性肾脏病（CKD）是全球健康关注和公共卫生重点。由于毒素的积累和炎性细胞因子的清除减少，这种情况通常涉及炎症，导致肾功能逐渐丧失。由于CKD的巨大负担，找到针对炎症的有效治疗策略至关重要.大量证据表明肾脏疾病与炎症体之间存在关联。作为一种众所周知的多蛋白信号复合物，NLR家族pyrin结构域包含3（NLRP3）炎症小体在诱导肾脏炎症和纤维化中起重要作用。靶向NLRP3炎性体的小分子抑制剂是治疗CKD的潜在药物。NLRP3炎症小体激活放大了炎症反应，促进细胞凋亡。因此，它可能有助于CKD的发作和进展，但CKD炎症小体激活背后的机制仍不清楚。在这次审查中,我们总结了有关NLRP3炎性体在CKD中的作用以及针对NLRP3炎性体的新策略的最新发现。
